BIO KEY INTERNATIONAL INC (BKYI): Nasdaq/NYSE listing notice — BIO-key receives Nasdaq non-compliance notice for late filings; plan due June 20

BIO KEY INTERNATIONAL INC

Nasdaq notified BIO-key on May 23, 2023 of non-compliance for failing to timely file Form 10-Q for Q1 2023.
Company was already delinquent on Form 10-K for year ended Dec 31, 2022.
Must submit compliance plan by June 20, 2023; if accepted, extension to Oct 16, 2023.
No immediate impact on listing or trading of common stock on Nasdaq Capital Market.
Form 12b-25 filed May 16, 2023 citing unreasonable effort to complete financial review.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

BIO KEY INTERNATIONAL INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

May 23, 2023, BIO-key International, Inc. (the “Company”) received notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”), due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the “Form 10-Q”). As previously reported, on April 18, 2023 the Company was notified by Nasdaq that is was not

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIO KEY INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-016136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.